Pancreatic Neuroendocrine Tumor Clinical Trial
Official title:
A Phase II Randomized,Controlled,Open Label,Multicentre Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor
A Phase II Randomized,Controlled,Open Label,Multicentre Study to evaluate the efficacy and safety of Tegafur combined with Temozolomide versus Tegafur combined with Temozolomide and Thalidomide in subjects with Advanced Pancreatic Neuroendocrine Tumor
Status | Recruiting |
Enrollment | 60 |
Est. completion date | September 2018 |
Est. primary completion date | October 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Patients should participate in the study voluntarily and sign informed consent; 2. Histopathological proven diagnosis of low and intermediate grade (G1, G2 or G3) advanced pancreatic neuroendocrine tumor( locally advanced, unresectable or distant Metastatic). For gastroenteropancreatic neuroendocrine tumor(GEP-NET),the classification is based on nuclear mitotic number and the Ki-67 index,which are as follows:G1:Nuclear mitotic number <2/10HPF,Ki-67 proliferative index =2%.G2: Nuclear mitotic number 2~20/10HPF,Ki-67 proliferative index 3%~20%.G3 Nuclear mitotic number >20/10HPF,Ki-67 proliferative index >20%; 3. Patients with advanced PNENs who had not been treated or had no more than two kinds of Systemic Anti-tumor Therapy,which could be somatostatin analogs, interferon, PRRT (peptide receptor radionuclide therapy), mTOR inhibitors, or chemotherapy (without any use of azole amines, fluorouracil,or thalidomide chemotherapy drugs); 4. Radiological documentation of tumor progression is required within 12 months prior to randomization; 5. At least one measurable lesion (byRECIST1.1); 6. ANC=1.5×109/L,PLT=100×109/L,HB=90g/L,TBIL=1.5ULN ;Without supportive care, ALT=2.5ULN and ALP=2.5ULN (without hepatic metastasis) ALT=5ULN and ALP=5ULN(with hepatic metastasis);serum creatin =1.5ULN and creatinine clearance rate =60ml/min;INR=1.5ULN and APTT =1.5ULN ; 7. ECOG PS:0-1; 8. Life expectancy of more than 12 weeks; 9. Men/Women of childbearing potential must agree to use a highly effective contraceptive method (such as double barrier contraceptive method,condom, oral or injectable contraceptives and intrauterine device) throughout treatment and for at least 90 days after study completion;All female patients will be considered fertile unless she has undergone natural menopause, artificial menopause or sterilization (such as hysterectomy, bilateral adnexal resection, or radioactive ovarian irradiation etc.) Exclusion Criteria: - 1?Diagnosed with high grade (G3) neuroendocrine carcinomas, adenocarcinoma, pancreatic islet cell carcinoma, goblet cell carcinoid, large cell neuroendocrine carcinoma, and small cell carcinoma; 2?Gastrointestinal tract, lung and thymus, and other unknown source of neuroendocrine tumors; 3?Functional NET which needs concomiant use of long-acting somatostatin analogues to control symptoms such as insulinoma, gastrinoma, glucagon tumor, somatostatin, ACTH tumor, VIP tumor, and carcinoid syndrome, Zollinger-Ellison syndrome or other disease-specific active symptoms.; 4?prior use of any VEGF/VEGFR targeted drugs and with disease progression during treatment; 5?Urine protein = ++,or Urine protein detected by quantitative test of 24h urinary protein>1.0 g; 6?Serum potassium and calcium (ionic or albumin binding) or magnesium exceed normal range and have clinical significance; 7? Blood pressure unable to be stably controlled(systolic pressure>140 mmHg,diastolic pressure>90mmHg); 8?gastrointestinal diseases or states judged by Investigators that could affect the absorption of the drug, including but not limited to active gastric and duodenal ulcers, ulcerative colitis or other gastrointestinal diseases or unresectable gastrointestinal tumor with active bleeding or other status that may cause gastrointestinal bleeding or perforation; 9?Patients have or had severe hemorrhage (bleeding volume >30ml within 3 months) , hemoptysis( fresh blood >5ml within 4 weeks ) or thromboembolic events (including transient ischemic attack) within 12 months; 10?Cardiovascular disease with significant clinical significance, including but not limited to acute myocardial infarction, severe / unstable angina or coronary artery bypass surgery within 6 months prior to enrollment; congestive heart failure (New York Heart Association (NYHA) classification> 2); ventricular arrhythmia requiring pharmacological treatment; left ventricular ejection fraction (LVEF) <50%; 11? Electrocardiogram (ECG) showed QT interval =480ms; 12?Patients suffered from other malignant tumors in the past 5 years,except radical resection of skin basal cells or squamous cell carcinoma, or cervical carcinoma in situ; 13?patients who have received anti-tumor therapy within 4 weeks prior to initiation of the study, including but not limited to chemotherapy, radiotherapy, bio-targeted therapy, immunotherapy, anti-tumor treatment of traditional Chinese medicine, hepatic artery embolization, hepatic metastatic cryoablation or radiofrequency ablation surgery; 14?patients who have received Palliative radiotherapy for bone metastaseswithin 2 weeks prior to initiation of the study ; 15?Any clinically significant active infection, including but not limited to HIV infection; 16?Patients with clinically significant liver disease history ,including but not limited to hepatitis B virus (HBV) infection (HBVDNA positive and copy number =1×104/ml); hepatitis C virus (HCV) infection,(HCVRNA positive and copy number=1×103/ml), or cirrhosis; 17?Patients had surgery (except biopsy) within 28 days or has surgical incision not fully healed prior to initiation of the study; 18?Patients with brain metastasis or spinal cord compression which had not surgical and / or radiation therapy,or which had previous treatment but there is no clinical imaging evidence proving the condition is stable; 19?The toxic reaction of previous anticancer treatment has not restored to grade 0 or 1 (except hair loss); 20?Patients participated in other drug clinical trials within 4 weeks and received drug treatment ; 21?Pregnancy(Pregnancy test positive before drug use)or lactation; 22?any other disease, metabolic abnormality, abnormal physical examination, or laboratory abnormalities estimated by investigators that make the patients not suitable to receive the study drug or will affect the interpretation of the study. |
Country | Name | City | State |
---|---|---|---|
China | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Chinese Academy of Medical Sciences |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Response Rate(ORR) | From randomization,each 6 weeks or 12 weeks(a year later) up to intolerance the toxicity or PD (up to 24 months) | ||
Secondary | Disease Control Rate(DCR) | From randomization,each 6 weeks or 12 weeks(a year later) up to intolerance the toxicity or PD (up to 24 months | ||
Secondary | Time to Tumor Response (TTR) | From randomization,each 6 weeks or 12 weeks(a year later)up to PD or death(up to 24 months) | ||
Secondary | Duration of Response(DOR) | From randomization,each 6 weeks or 12 weeks(a year later) up to PD or death(up to 24 months) | ||
Secondary | Progression free survival(PFS) | From randomization,each 6 weeks or 12 weeks(a year later)(a year later) up to PD or death (up to 24 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05566093 -
EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors
|
N/A | |
Completed |
NCT00970970 -
Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
|
||
Recruiting |
NCT05568017 -
Neoadjuvant PRRT With Y-90-DOTATOC in pNET
|
Phase 2 | |
Not yet recruiting |
NCT06024343 -
Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Repair or Reconstruction
|
N/A | |
Recruiting |
NCT03891784 -
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
|
Phase 2 | |
Completed |
NCT00804336 -
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
|
Phase 1 | |
Recruiting |
NCT05997056 -
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
|
Phase 2 | |
Not yet recruiting |
NCT06158516 -
A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Recruiting |
NCT04119024 -
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05040360 -
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Completed |
NCT00576680 -
RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05610826 -
Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03074513 -
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
|
Phase 2 | |
Completed |
NCT03967951 -
CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms
|
||
Completed |
NCT01024387 -
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Not yet recruiting |
NCT03435770 -
Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms
|
N/A | |
Recruiting |
NCT04134832 -
Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region
|
||
Recruiting |
NCT05554744 -
EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors
|
N/A | |
Completed |
NCT02159989 -
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
Not yet recruiting |
NCT06406387 -
ATRX/DAXX in EUS-FNB Specimens of Pan-NETs
|